IGM Biosciences Inc

IGM Biosciences Inc (IGMS) Stock Analysis

$1.270

-0.029 (-2.31%)At close

Loading chart…
High
1.300
Open
1.300
VWAP
1.28
Vol
1.62M
Mkt Cap
390.15M
Low
1.270
Amount
2.07M
EV/EBITDA, TTM
2.09

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

igmbio.com

Valuation Metrics

The current forward P/E ratio for IGM Biosciences Inc (IGMS) is -1.45, compared to its 5-year average forward P/E of -3.40.

Forward P/E

Fair
5Y Average P/E
-3.40
Current P/E
-1.45
Overvalued
-1.20
Undervalued
-5.60

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
-1.68
Current EV/EBITDA
2.09
Overvalued
0.59
Undervalued
-3.95

Forward P/S

Fair
5Y Average P/S
91.57
Current P/S
11.79
Overvalued
213.55
Undervalued
-30.41

Alphio AI Price Scenarios for IGMS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IGMS

$1.69

Scenario price

B

Base

Base · 50%IGMS

$1.50

Scenario price

B

Bear

Bear · 25%IGMS

$1.02

Scenario price

Events Timeline

2025-07-01 (ET)

09:04:30

IGM Biosciences be acquired by Concentra for $1.247 in cash per share

2025-01-09 (ET)

12:10:54

IGM Biosciences reducing workforce by 73%, evaluating strategic alternatives

12:09:04

IGM Biosciences halting further development of imvotamab and IGM-2644

2024-11-08 (ET)

06:06:50

IGM Biosciences reports Q3 EPS ($1.01), consensus (80c)

Show More Events

News

Show More News

IGMS FAQ — answered by Alphio AI

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started